India’s pharmaceutical exporters are bracing for a major financial hit as the ongoing conflict involving the United States and Iran disrupts key shipping routes and sharply increases freight costs. Industry estimates suggest that the sector could face losses of up to ₹5,000 crore if the disruptions continue through the coming weeks. The concern comes at a time when the pharmaceutical industry plays a crucial role in India’s exports and supplies medicines to several regions around the world.
The primary challenge stems from rising logistics expenses and shipping disruptions linked to the conflict in the Middle East. The Strait of Hormuz, one of the world’s most important maritime chokepoints for energy and cargo shipments, has seen severe disruptions after military tensions escalated in late February. The crisis has led many global shipping companies to suspend or reduce transit through the region due to safety concerns, forcing exporters to seek alternative routes or pay higher freight charges.
Industry executives say the impact is already visible. Freight costs for pharmaceutical shipments have increased sharply, with surcharges ranging from $3,500 to $5,000 per container and, in some cases, reaching even higher levels. In addition, some shipping lines are reportedly refusing cargo destined for certain Gulf hubs due to rising security risks. These developments have made it significantly more expensive and complicated for Indian drugmakers to move both raw materials and finished medicines across international markets.
West Asia’s Strategic Role in India’s Drug Trade:
The Middle East plays a critical role in India’s pharmaceutical export ecosystem. West Asia accounts for roughly 5–6 percent of India’s total pharmaceutical exports, which are valued at more than $30 billion annually. Beyond direct consumption, the region also serves as a crucial transit hub for shipments headed to markets in Africa, Europe, and North America. Dubai, in particular, functions as a major logistics centre where pharmaceutical products are consolidated and redistributed to multiple destinations. Any disruption in this trade corridor therefore has ripple effects across the entire global supply chain. If shipments to West Asia are significantly delayed or halted, the loss in export value could quickly escalate into thousands of crores of rupees.
The situation is particularly worrying for exporters that rely heavily on Gulf markets such as the United Arab Emirates, Saudi Arabia, Oman, Kuwait and Yemen. These countries depend on India for affordable generic medicines, making uninterrupted trade essential not only for Indian exporters but also for healthcare systems across the region.
Supply Chain Challenges and Rising Input Costs:
The conflict has not only affected export logistics but also the supply chain of raw materials used in pharmaceutical manufacturing. Many Indian drugmakers import bulk drug ingredients and intermediates from countries such as China. Freight charges for these shipments have also surged, with container rates reportedly doubling in some cases.
Shipping companies are increasingly avoiding routes through conflict areas or demanding higher war-risk premiums. As a result, enterprises are dealing with both higher input costs and growing transportation costs. According to analysts, this combination might compress exporters’ earnings, particularly those operating on tight profit margins in the generics industry. To prevent expected disruptions, some pharmaceutical businesses have been stockpiling additional inventory and researching alternate transportation routes. However, such procedures involve additional expenses and logistical complexity. In extreme cases, businesses may have to renegotiate contracts with international buyers or pay a portion of the increased freight costs.
Industry Looks for Stability as Conflict Continues:
The broader geopolitical situation continues to evolve, and industry leaders are closely monitoring developments in the Middle East. Global supply chains have already been under pressure in recent years due to pandemic-related disruptions and geopolitical tensions. The current conflict has added another layer of uncertainty, particularly for industries dependent on maritime trade routes. Experts believe that if shipping disruptions persist for a prolonged period, the pharmaceutical sector could face temporary shortages, delivery delays, and rising export costs. At the same time, higher oil prices triggered by the conflict could further increase transportation and production expenses across the global economy.
Despite the difficulties, India’s pharmaceutical sector is still strong and essential to the global supply of reasonably priced medications. However, exporters caution that ongoing political instability in strategic maritime areas might severely hamper trade and reduce Indian pharmaceutical businesses’ capacity to compete in global markets. In order to avoid what may turn out to be one of the worst short-term shocks to India’s pharmaceutical export industry in recent years, the industry is currently hoping that shipping routes stabilize quickly and freight costs return to normal levels.
